Literature DB >> 15829293

Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes.

William J Magner1, Thomas B Tomasi.   

Abstract

We have recently reported, in a murine tumor model, that apoptotic cells induced by different agents may vary in their ability to elicit host immunity. The basis for this observation is unclear but may involve varying efficiencies of cross-presentation and/or direct activation of immunity by different apoptotic preparations. As a first step in addressing this issue, we compared expression patterns of selected immune genes (MHC class I, class II, CD40, B7-1, B7-2) on viable and apoptotic populations induced by four different agents. The histone deacetylase inhibitor trichostatin A (TSA) induced MHC class II expression on viable and apoptotic cell populations, while LPAM, H2O2 and gamma-irradiation did not activate class II. Each agent employed elicited a different expression pattern of costimulatory molecules (CD40, B7-1, B7-2) on both apoptotic and 7-AAD+ 'necrotic' populations. In striking contrast to the TSA induction of MHC class II, class I cell surface protein was diminished on the apoptotic populations. These effects were not a result of changes in the cell cycle produced by the various treatments. The data demonstrate that distinctive gene expression patterns on viable and apoptotic cells are elicited by different apoptosis inducing agents. We discuss how expression patterns on dead or dying tumor cells could potentially affect the tumor's ability to elicit immunity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15829293     DOI: 10.1016/j.molimm.2004.09.030

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

Review 1.  Photodynamic therapy and anti-tumour immunity.

Authors:  Ana P Castano; Pawel Mroz; Michael R Hamblin
Journal:  Nat Rev Cancer       Date:  2006-07       Impact factor: 60.716

2.  Intracellular activated Notch1 is critical for proliferation of Kaposi's sarcoma-associated herpesvirus-associated B-lymphoma cell lines in vitro.

Authors:  Ke Lan; Tathagata Choudhuri; Masanao Murakami; Daniel A Kuppers; Erle S Robertson
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

3.  Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects.

Authors:  Ta-Chiang Liu; Pedro Castelo-Branco; Samuel D Rabkin; Robert L Martuza
Journal:  Mol Ther       Date:  2008-04-01       Impact factor: 11.454

4.  The epigenetic regulation of Dicer and microRNA biogenesis by Panobinostat.

Authors:  Nicholas C Hoffend; William J Magner; Thomas B Tomasi
Journal:  Epigenetics       Date:  2016-12-09       Impact factor: 4.528

5.  Necroptotic debris including damaged mitochondria elicits sepsis-like syndrome during late-phase tularemia.

Authors:  Anju Singh; Sivakumar Periasamy; Meenakshi Malik; Chandra Shekhar Bakshi; Laurie Stephen; Jeffrey G Ault; Carmen A Mannella; Timothy J Sellati
Journal:  Cell Death Discov       Date:  2017-09-25

6.  An epigenetic vaccine model active in the prevention and treatment of melanoma.

Authors:  A Nazmul H Khan; William J Magner; Thomas B Tomasi
Journal:  J Transl Med       Date:  2007-12-10       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.